Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6461247 | 0.93 | — | — | |
| SCHEMBL12561015 | 0.81 | CYP1A2 (0.50) | CYP1A2ADRA2A | |
| SCHEMBL9550257 | 0.77 | CYP1A2 (0.59) | CYP1A2ADRA2A | |
| SCHEMBL8328456 | 0.75 | — | — | |
| SCHEMBL8329095 | 0.75 | — | — | |
| SCHEMBL23844550 | 0.75 | CYP1A2 (0.57) | CYP1A2ADRA2ACHRNB2 | |
| SCHEMBL2662411 | 0.75 | — | — | |
| SCHEMBL1371554 | 0.75 | CYP1A2 (0.57) | CYP1A2ADRA2ACHRNB2 | |
| SCHEMBL5675269 | 0.74 | — | — | |
| Cyanide SCHEMBL30212639 | 0.74 | CYP1A2 (0.52) | CYP1A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-14 | — | — | US | disclosed |
| CN-102471346-B | Tricyclic inhibitors of JAK | HOFFMANN LA ROCHE | 2014-05-14 | — | — | CN | disclosed |
| US-8361962-B2 | Tricyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2459566-A1 | TRICYCLIC INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| CN-102471346-A | Tricyclic inhibitors of JAK | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | disclosed |
| WO-2011012540-A1 | TRICYCLIC INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | BILLEDEAU ROLAND JOSEPH | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | CGAS, SSB, FPGS | CYP1A2 1473/4885ADRA2A 2293/4885CHRNB2 3850/4885 |
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | JAK3, JAK1, JAK2 | CYP1A2 1039/4885ADRA2A 3143/4885CHRNB2 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.